Anil Kane, Ph.D.
Global Head of Technical and Scientific Affairs, Pharma Services Group, Thermo Fisher Scientific
Anil Kane, Ph.D., Global Head of Technical and Scientific Affairs, Pharma Services Group, Thermo Fisher Scientific: Oral solid dose forms are really very, very patient friendly as these apply in different age groups from teens to adults or geriatric patients, and oral solid dosage forms are easy to self-administer or administer by a clinician or a caregiver as compared to other dosage forms.
Oral solid dosage forms are going to stay as a popular dosage form primarily because they are patient-friendly dosage forms. Also, from the development perspective, optimizing the drug delivery and targeting the drug delivery is possible with oral delivery. Oral solid dosage forms can be developed using a variety of different techniques based on the properties and the absorption distribution, metabolism, and excretion profiles, and optimizing the efficacy of these molecules by oral drug delivery is going to be feasible. Targeting drug delivery in the stomach in the small intestine or in the distal part of the intestine is easily feasible with the technologies we have today. So whether it’s developing sustained-release dosage forms, modified-release dosage forms, or targeted drug delivery, whether it is for a single ingredient or fixed-dose combinations, designing the right release profile of small molecules is feasible in older, solid-dose delivery. If we look at the FDA approvals, 20 of the drug products were approved out of 37 approved by the FDA in 2022. This confirms and proves that older solid dosage forms are going to be popular dosage forms as compared to other dosage forms and delivery groups.